Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate

Aspire Biopharma Holdings, Inc.

Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.
Combined with prior closing of 13,750 shares ($11M including $943,801 debt conversion), total 30,000 shares designated.
Company believes stockholders' equity now exceeds $2.5M minimum for continued Nasdaq listing.
Certificate of Amendment filed Apr 13, 2026 designating 30,000 Series A shares with $1,000 stated value each.
Conversion price set at 80% of lowest closing price over 5 days before conversion; floor price at 20% of Nasdaq Minimum Price.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aspire Biopharma Holdings, Inc.: Filed a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock, clarifying and restating provisions relating to designation and number of shares to 30,000 shares of Series A Convertible Preferred Stock (effective 2026-04-13).

Change: charter amendment
Effective: 2026-04-13

Exact text from the filing

On April 13, 2026, Aspire Biopharma Holdings, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Amendment”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors (effective 2026-02-06).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Effective: 2026-02-06

Exact text from the filing

on February 6, 2026, Aspire Biopharma Holdings, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”)

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Aspire Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-017115

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.